Ye Jingmei, Wang Jiani, Tan Li, Yang Shaojiang, Xu Lihua, Wu Xiaohong, Deng Huaifu, Tan Huo
Department of Blood Transfusion, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou 510630, China.
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9089-96. eCollection 2015.
The objective of this study was to analyze the expression of TARBP1 and its clinical significance in hepatocellular carcinoma (HCC).
90 patients with primary hepatocellular carcinoma were included in this study. The tumor and paired adjacent non-tumor tissues were collected. TARBP1 expression was assessed by quantitative real-time polymerase chain reaction and immunohistochemistry. Associations of TARBP1 expression with the clinicopathological features were analyzed, and prognosis of HCC patients was evaluated.
The result show the expression of TARBP1 mRNA in liver cancer tissues were higher than in the adjacent normal liver tissues in 10 paired samples (P=0.0015). Compared with adjacent normal liver tissues, overexpression of TARBP1 was detected in 61.1% (55/90) HCC patients. TARBP1 expression was associated with the AJCC tumor stage (P=0.004) and clinical stage (P=0.005), and decreased overall survival (P=0.002). In multivariate analysis, TARBP1 expression was an independent prognostic factor for overall survival (Hazard ratio [HR]=2.773, 95% confidence interval [CI] 1.542-4.985; P=0.019).
TARBP1 is up-regulated in HCC, and the expression of TARBP1 was associated with the pathological grading and clinical stage. TARBP1 maybe is an independent prognostic marker of HCC patients.
本研究旨在分析TARBP1在肝细胞癌（HCC）中的表达及其临床意义。
本研究纳入90例原发性肝细胞癌患者。收集肿瘤组织及配对的癌旁非肿瘤组织。采用定量实时聚合酶链反应和免疫组织化学法评估TARBP1表达。分析TARBP1表达与临床病理特征的相关性，并评估HCC患者的预后。
结果显示，在10对样本中，肝癌组织中TARBP1 mRNA的表达高于癌旁正常肝组织（P = 0.0015）。与癌旁正常肝组织相比，61.1%（55/90）的HCC患者检测到TARBP1过表达。TARBP1表达与美国癌症联合委员会（AJCC）肿瘤分期（P = 0.004）和临床分期（P = 0.005）相关，并降低总生存期（P = 0.002）。多因素分析显示，TARBP1表达是总生存期的独立预后因素（风险比[HR]=2.773，95%置信区间[CI] 1.542 - 4.985；P = 0.019）。
TARBP1在HCC中上调，其表达与病理分级和临床分期相关。TARBP1可能是HCC患者的独立预后标志物。
